Annovis Bio, Inc.’s novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population. Annovis is a clinical stage, drug platform company focused primarily on drugs for chronic neurodegeneration—AD, its orphan indication AD-DS and PD. Additionally, they have a compound to treat acute neurodegeneration—traumatic
…More brain injury (TBI) and stroke—and a third compound for advanced AD.